Novo Nordisk

News

Novo Nordisk nears EU approval of obesity drug Wegovy

Danish drugmaker Novo Nordisk is hoping to launch its once-weekly injectable treatment for obesity, Wegovy, in the EU next year after getting a green light from the EMA's human medicines co

News

Lilly grabs glucose-sensing insulin tech, buying Protomer in...

Eli Lilly bought a stake in Protomer Technologies and its glucose-sensing insulin platform last year, and it must like what it has seen in the programme since then – it has just agreed to b

News

Novo Nordisk bulks up in rare diseases with $1.2bn Prothena ...

Diabetes giant Novo Nordisk has opened a new front in its rare disease R&D, thanks to an acquisition agreement with Prothena focusing on drugs for ATTR amyloidosis.

Sales & Marketing

Pharma sales rep talking to a GP over video conferencing

Experts discuss the field force’s customer-centric future

The ways in which HCPs prefer to engage with pharma has been changing for quite some time, and the digital transformation brought by COVID has dramatically accelerated that.

News

FDA ends 7-year obesity drug drought, clearing Novo Nordisk'...

Novo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which it believes has the potential to redefine the market for weight-loss medicine

News

Novo Nordisk crowns cell therapy pipeline with $598m Heartse...

Novo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed by Japanese startup Heartseed.

Novo Nordisk nears EU approval of obesity drug Wegovy

Lilly grabs glucose-sensing insulin tech, buying Protomer in...

Novo Nordisk bulks up in rare diseases with $1.2bn Prothena ...

Experts discuss the field force’s customer-centric future

FDA ends 7-year obesity drug drought, clearing Novo Nordisk'...

Novo Nordisk crowns cell therapy pipeline with $598m Heartse...

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Novo Nordisk

Editor's Picks